Lacosamide-structure (Lacosamide Structure)
Lacosamide Injection
Product Images NDC 72266-242
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 72266-242). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Fosun Pharma Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Lacosamide Carton Label (Lacosamide Carton Label)
This is a medication guide for Lacosamide Injection, USP, which is a 200 mg/20 mL solution for infusion. It is intended for intravenous use only and comes in 5 x 20 mL single-dose vials. The medication guide should be dispensed to each patient. The inactive ingredients are sodium chloride, hydrochloric acid, and water for injection. Dosage information can be found in the package insert. The medication should be stored at 20°C to 25°C (68°F to 77°F), and any unused portion should be discarded. The medication is distributed by Fosun Pharma USA Inc. and is made in India. The provided code number is TS/DRUGS/2/2015.*
Lacosamide Vial Label (Lacosamide Container Label)
This is a description of a medication called Lacosamide Injection, which is distributed by Fosun Pharma USA Inc in Princeton, NJ. It is made in India and is for intravenous use only. It comes in a single-dose vial and has a code number of TS/DRUGS/2/2015 and a GTIN of 00372266242013. The lot number is not available due to an unvarnished area on the label. The concentration is 10mg/mL and it comes in a 20mL vial.*
Lacosamide-figure-1 (Lacosamide Figure 1)
The text contains a figure showing the percent reduction in seizure frequency per 28 days during the maintenance phase by dose for three different studies. Study 2 had a 5% reduction in seizures, while Study 3 had a 21% reduction. The figure also includes data on placebo and Lacosamide, showing a statistically significant difference in seizure reduction compared to placebo for Lacosamide at doses of 200, 400, and 600. No other information is available.*
Lacosamide-figure-2 (Lacosamide Figure 2)
This is a description of a figure (Figure 2) that shows the proportion of patients (in percentage) sorted by responder rate for Lacosamide and placebo groups in studies 2, 3, and 4. The text includes a table with 10 columns representing the responder rate, the number of patients (in N), and the percentage of patients in each category. There are also some symbols and characters that may represent technical notations.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
